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Background: Tuberculosis (TB) is a major problem in Russia, particularly regarding
multidrug-resistant tuberculosis (MDR-TB). Rapid drug susceptibility testing methods are
therefore needed.
Objectives:To perform epidemiological analyses of TB in the Archangelsk region and to eval-
uate the molecular method GenoTypeMTBDRplus in this type of setting.
Materials and methods:Clinical and microbiological data of all TB patients in Archangelsk
were collected in 2010. Smear-positive sputa were analysed by MTBDRplus and Bactec MGIT
960.
Results:The number of TB cases was 812 (incidence 65/105) and among these patients, 151
cases were registered in the penitentiary system (incidence 1162/105). Most patients were
men, 94% had pulmonary TB and 22% were relapses. Out of all cases, 341 (42%) were smear
positive and thus contagious and 176 (22%) had MDR-TB, among which one had extensively
drug resistant tuberculosis (XDR-TB). Furthermore, two TB patients had strains being resis-
tant to rifampicin, but susceptible to isoniazid. The number of cases being both contagious
and MDR-TB was 128 representing 15.8% of all TB cases (incidence 10.2/105). Among these
128 TB patients 37 were relapses representing 25.7% of all the relapse cases. The results of
MTBDRplus and Bactec MGIT analyses corresponded in 98.8%.
Conclusions:In Archangelsk many TB patients had contagious MDR-TB thus being hazardous
in society and relapsing pulmonary TB was common. The TB situation in the prisons was
particularly severe. The analyses showed furthermore that MTBDRplus is of major value in
this setting.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.ades [1–3]. The Russian Federation is a high burden country in
Introduction
Tuberculosis (TB) is a major problem worldwide [1]. Particu-
larly severe is the fact that the number of multidrug resistant-African Society for Myco
inska.se, lars-olof.larssontuberculosis (MDR-TB) cases has increased during the last dec-
this respect; 18% of all new TB cases were registered as
MDR-TB in 2010 [1]. In addition, extensively drug resistantbacteriology. Published by Elsevier Ltd. All rights reserved.
@vgregion.se (L.-O. Larsson).
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[4]. A high prevalence of resistant TB decreases the treatment
success rates [2,5] and increases mortality [6], thus represent-
ing a severe public health problem. Rapid sensitivity results
enable an early start of appropriate treatment, shorten the
time of hospitalization and has a favorable epidemiological
impact since the spread of resistant strains is repressed. There
is an imperative need for rapid drug susceptibility testing
methods considering the increase of resistant Mycobacterium
tuberculosis strains worldwide. Such methods enable appropri-
ate clinical care and guidance to optimal treatment regimes.
Bactec MGIT 960 (BD, Sparks, MD, USA) and the absolute
concentration method on Lo¨wenstein-Jensen (L-J) medium
are important tools in the diagnosis of MDR-TB [7,8]. The for-
mer can take from 20 to 35 days until the drug susceptibility
test results are obtained and the L-J method takes an even
longer time.
Molecular Line Probe assays reveal mutations in DNA of M.
tuberculosis and permit rapid analyses of rifampicin and isoni-
azid resistance of smear positive sputa [9–12]. Presently, the
Genotype MTBDRplus assay (Hain Lifescience GMbH, Neh-
ren, Germany) has become widely used. Such assays can
determine drug resistance in two days and are recommended
by the World Health Organization (WHO) to detect cases of
MDR-TB [13]. Numerous studies performed in different set-
tings have provided reliable data with high specificity and
sensitivity using this assay [9–18]. These studies also include
analyses from The Russian Federation [11] and other parts of
the former Soviet Union [14]. The Archangelsk region of The
Russian Federation is a hot spot for MDR TB with 23.8%
MDR TB registered among the new cases in 2008 (2) and
25,8% in 2009 (19). Genotype MTBDRplus assay was introduced
in 2009 in this high MDR-TB setting for rapid detection of drug
resistant TB cases.
The aim of this study was twofold: to perform epidemio-
logical analyses of TB in the Archangelsk region with a partic-
ular focus on MDR-TB, and to evaluate the molecular method
MTBDRplus assay in this high burden setting.
Materials and methods
Population-based study
The epidemiological analyses were performed at the Regional
Clinical Antituberculosis Dispensary in Archangelsk, Russia.
The specialized TB control services in the Archangelsk region
consist of the dispensary as well as outpatient departments in
general hospitals and clinics, adapted to the principles of TB
control in The Russian Federation [20]. The surveillance of
TB incidence in the region was performed by the Statistical
Department at the Regional Clinical Antituberculosis Dispen-
sary. It is mandatory to register all TB cases as well as treat-
ment outcomes and diagnostic results. Data were registered
and analyzed according to the recommendations by WHO
and the Russian laws and directions. The data were reported
and presented annually in a regional, national and interna-
tional context [19].
Each case was registered as either a new or a relapse case.
A new case of TB was defined as a patient with newly
diagnosed TB without previously known TB. A relapse casewas defined as a patient previously treated for TB based on
clinical, bacteriological and/or radiological findings who had
been declared cured, or treatment completed, and then diag-
nosed again with TB. Non-pulmonary TB refers to disease in
which the initial infection was not in the lung [21] and pul-
monary TB refers to disease in the lung due to lesions from
a pulmonary focus. Age and gender were registered for all pa-
tients and whether or not they belonged to the civil sector or
the penitentiary system. All TB patients were routinely tested
for HIV, while other concomitant diseases, apart from HIV,
were not registered in the present study.
Specimen collection and microbiological analyses
Sputum samples were collected at the central dispensary if
the patients were hospitalized, and at the district TB wards
if the patients were receiving treatment at the outpatient
departments. Three sputum samples were available for each
patient, and these were sent to the Laboratory of the Regional
Clinical Antituberculosis Dispensary for microscopy, culture
and drug susceptibility testing (DST). Direct microscopy was
performed on all three samples. Two of the samples were cul-
tured on L-J medium and one on Bactec MGIT liquid medium,
with subsequent cultured DST for first-line drugs using Bac-
tec MGIT [7,8,22], and second-line drugs using the method
of absolute concentrations on L-J medium [23].
Comparisons of two drug susceptibility testing methods
Smear-positive samples from the patients of the civil sector
were analysed for susceptibility patterns by the GenoType
MTBDRplus [9–12] according to the instructions of the manu-
facturers [9–12] and the results were compared with those of
the Bactec MGIT 960. When the susceptibility patterns dif-
fered using these two methods, the method of absolute con-
centrations on L-J medium was used.
Ethical permission
This study was approved by the ethical committee of the
Northern State Medical University, Archangelsk, Russian Fed-
eration on June 4, 2010 (approval protocol No. 07/06).
Results
In total, 812 TB cases were registered in the year 2010 in the
Archangelsk region (incidence 65/100,000): 661 in the civil sec-
tor and 151 in the penitentiary system. The Archangelsk re-
gion has a population of 1,254,499 in the civil sector and
almost 13,000 in the penitentiary system, and the incidence
was thus 53/100,000 in the civil sector and 1,162/100,000 in
the penitentiary system.
Table 1 shows the epidemiological situation among the
812 TB patients in Archangelsk in the year 2010. The new
cases represented 668 (82%), and the relapses 144 (18%) pa-
tients. A majority of the patients in the civil sector were
men, and the male dominance was particularly high among
the relapses. In the penitentiary system, all patients were
men, which is due to the fact that prisons for women were
located in other regions. Most patients were aged in their
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those in the civil sector. Most patients had pulmonary TB, par-
ticularly the relapse cases. In total, 23 (2.8%) of the TB patients
were HIV infected and most of them were prisoners. Only 2
patients were immigrants. There were 8 cases of TB in chil-
dren aged 0–5 years and 8 cases aged 6–15 years, i.e., 0.9%
among all TB cases were children.
Among all the 812 TB cases, 521 (64%) were bacteriological
confirmed, and 341 (42%) were smear positive and thus conta-
gious. Furthermore, 176 (22%) patients had MDR strains,
among whom 1 had an XDR strain, and 2 patients had strains
resistant to rifampicin, but susceptible to isoniazid; 5% (45
patients) carried strains resistant to isoniazid, but susceptible
to rifampicin. The number of MDR-TB among the new cases
was 122 (18%). Data on drug resistance, including those for
the second line drugs, are shown in Table 2.
The number of TB cases having both contagious and
MDR–TB was 128, representing 15.8% of all the 812 TB cases
and an incidence of 10.2/100,000. Among these, 128 TB
patients, 91 were new cases representing 13.6% of all the
668 new cases, and 37 were relapse cases representing
25.7% of all the 144 relapse cases.
The MTBDRplus assay was implemented in the routine lab-
oratory practice in Archangelsk in 2010. Out of the 297 smear-
positive pulmonary TB cases diagnosed in the civil sector, 211
cases were available for the MTBDRplus assay and comparison
analyses. Thus, 86 cases were not available for comparison
analyses and among them 59 patients were admitted as
smear-negative according to the preliminary results from
other health care facilities. Furthermore, 14 patients were
not included since it was primarily not known whether they
were new cases or relapses (usually non-local residents), 7 pa-
tients died before definitive diagnosis, while no samples from
them were sent to the Laboratory of the Regional Clinical
Antituberculosis Dispensary, and 6 patients were residents
from a remote area and it was not possible to obtain the re-
quested amount of sputa for the validation procedure.
The results from MTBDRplus and Bactec MGIT 960 DST for
these 211 cases were compared. However, 7 specimens did
not give any interpretable results of the MTBDRplus assay ow-
ing to overall weak signals of the strips, and 31 strains did not
grow or were contaminated. For 173 patients, the results of
MTBDRplus were compared with DST by Bactec MGIT 960.
Thus, the results of 173 cases remained, among which 153Table 1 – Epidemiological characteristics of the 812 TB patients.
Civil sector
Number of TB cases 661
New cases Rela
Number 574 87
Male (%) 385 (67) 70 (8
Age years median (SD*) 42 (14) 46 (1
Pulmonary TB (%) 533 (93) 83 (9
HIV infected (%) 7(1) 0
Smear-positivity (%) 252 (44) 45 (5
MDR (%) 109 (19) 39 (4
# Prisons for women were located in other regions than in Archangelsk.
* SD (Standard deviation).represented new cases and 20 relapses. Median time for re-
sults of MTBDRplus and Bactec MGIT was 8 and 28 days
respectively in the present setting.
Comparison of the results from MTBDRplus and Bactec
MGIT 960 DST is given in Tables 3 and 4. As is seen from the
tables, the results were in concordance but for 5 cases (3%).
All of the discrepant cases were male and new cases of TB.
In three cases out of the five, the Bactec MGIT revealed isoni-
azid resistance, though MTBDRplus showed susceptibility
which was confirmed by the absolute concentration method
on L-J media. On the other hand, for the other two cases,
the MTBDRplus revealed rifampicin resistance, while both
Bactec MGIT and L-J showed susceptibility.
The present analyses based on the MTBDRplus technique
revealed that the majority of isoniazid resistant isolates
(N = 85; 95.5%) had mutations in codon 315 of the katG gene,
including seven strains in which the inhA gene also harbored
a mutation. In the majority of rifampicin resistant cases
(N = 63; 91.3%), codon 531 of the rpoB gene was mutated.
In one case, both wild type and mutation probes were reg-
istered in the katG and rpoB genes simultaneously, in one
case only in rpoB gene and in 4 cases only in katG gene. All
these 6 cases were defined as resistant to drug or drugs
according to the mutations revealed by MTBDRplus, results
that were subsequently confirmed by DST, i.e., no discrepant
results in the two methods were observed in this group.
Discussion
In the present study from Archangelsk, Russia, it was shown
that an absolute majority of the TB cases had pulmonary TB
whereof more than 40% of the cases were contagious, i.e.,
smear positive in a predominantly male patient group. The
incidence of TB in the penitentiary system was 1,162/
100,000, i.e., being more than 20 times higher than in the civil
sector, which shows that the situation in the prisons is most
severe. Incidence figures over 1000 indicate that practically all
inmates have been exposed to TB.
As expected, HIV positivity was much more common
among the inmates; more than 10% of the TB patients were
also HIV positive. In contrast, only 1% of the civilian TB pa-
tients were HIV positive.
The number of MDR-TB cases was high–22% of all the
cases–but only one had XDR-TB. Particularly among the civil-Penitentiary system#
151
pse cases New cases Relapse cases
94 57
0) 94 (100) 57 (100)
2) 34 (10) 38 (10)
5) 90 (96) 57 (100)
9 (10) 7 (12)
2) 26 (28) 18 (32)
5) 13 (14) 15 (26)
Table 2 – Drug susceptibility testing results in Archangelsk region in 2010.
Civil sector Penitentiary system
New cases Relapses New cases Relapses
Total number of patients with DST results 316 55 35 21
Number % Number % Number % Number %
No drug resistance detected 124 39.2 7 12.7 10 28.6 4 19
Drug resistance detected 192 60.8 48 87.3 25 71.4 17 81
Isoniazid 144 45.6 43 78.2 18 51.4 16 76
Rifampicin 111 35.1 39 70.9 13 37.1 15 71
Streptomycin 171 54.1 43 78.2 23 65.7 17 81
Ethambutol 98 31.0 32 58.2 11 31.4 10 48
Pyrazinamide 24 7.6 8 14.5 1 2.9 0 0
Kanamycin 14 4.4 5 9.1 6 17.1 4 19
Capreomycin 9 2.8 3 5.5 1 2.9 0 0
Ofloxacin 3 0.9 3 5.5 2 5.7 0 0
Prothionamide 26 8.2 18 32.7 1 2.9 0 0
PAS 24 7.6 3 5.5 5 14.3 3 14
Cycloserine 6 1.9 0 0.0 2 5.7 1 5
Table 3 – Comparison of Bactec MGIT and MTBDRplus: the number of resistant strains is given.
New cases Relapses
Total number of strains 153 20
Bactec MGIT MTBDRplus Bactec MGIT MTBDRplus
Isoniazid 73 (48%) 70 (46%) 16 (80%) 16 (80%)
Rifampicin 55 (36%) 57 (37%) 14 (70%) 14 (70%)
MDR 55 (36%) 57 (37%) 14 (70%) 14 (70%)
Table 4 – Sensitivity, specificity of MTBDRplus assay and rate of matching results.
Matching results (%) Sensitivity (%) Specificity (%)
Isoniazid 98.3 96.6 (95 CI 89.899.1) 100.0 (95 CI 94.6100.0)
Rifampicin 98.8 100.0 (95 CI 93.4100.0) 98.1 (95 CI 92.599.7)
MDR 98.8 100.0 (95 CI 92.599.7) 98.1 (95 CI 92.599.7)
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high–45% of all these cases. The number of patients being
both smear positive, i.e., contagious and MDR-TB, was 128,
representing 16% of all cases (incidence 10/100,000). Among
all civilian relapse cases, 45% belonged to this group. The
large number of contagious MDR cases is hazardous in society
and stresses the necessity of rapid methods to analyze drug
susceptibility.
The incidence of TB declined steadily in The Soviet Union/
The Russian Federation until 1990 [20] owing to socio-eco-
nomic improvement and implementation of a strict control
program with miniature-chest-X-ray and tuberculin skin test-
ing. A mass BCG-vaccination program was performed as well.
The TB situation then worsened and the incidence peaked in
2000: 91/100,000 in Russia and 104/100,000 in the Archangelsk
region, but the increase has since then been halted [24]. In the
year 2010 Russian authorities estimated the incidence to be
77/100,000 in the entirety of Russia [24], and this research
demonstrates an incidence of 65/100,000 in Archangelsk dur-ing the same year in the present study. The incidence was
thus lower in Archangelsk compared with Russia as a whole.
This may be attributed to several factors, e.g., the incidence of
HIV is comparatively low in Archangelsk and the immigrants
are few. Another explanation may be that the regional medi-
cal health authorities have allocated substantial resources for
bacteriological diagnosis of TB, supervised treatment of TB
cases according to international consensus, and social sup-
port to those in need through aid programs. The Archangelsk
region is furthermore not densely populated (approximately
2.2 individuals per square kilometer) and urbanization is gen-
erally considered to facilitate the spread of TB [25]. However,
recent Russian studies have demonstrated an increased prev-
alence of TB in a non-urban setting [26], which might be due
to less accessibility to health care facilities in rural areas. The
information shows that TB is an epidemiological complex dis-
ease and its incidence is owing to many factors.
Even if the incidence has decreased in many Russian re-
gions, there has been a steady increase in MDR-TB cases,
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study, many TB cases were not bacteriological confirmed
why the true number of MDR-TB cases is expected to be high-
er than 22% and similar conditions might also concern XDR-
TB.
It is of interest to note that during 2010 only one patient
was diagnosed with XDR-TB in Archangelsk. Several patients
with XDR-TB had been diagnosed during previous years and
data from other Russian regions also show higher figures
[27]. An explanation of the very low number is that a special
in-patient department for XDR-TB patients has been estab-
lished to treat all XDR-TB patients, including those from the
penitentiary system. All TB strains are furthermore evaluated
for second-line drugs. It is also of interest that the immigrants
are very few in the Archangelsk region.
The TB patients were usually suffering from pulmonary
TB, which may be attributed to the dominance of the Beijing
strain in this area [4,28,29], as well as low prevalence of TB
and HIV co-infection. In addition, extrapulmonary cases can
sometimes be more difficult to diagnose through bacteria,
and may have a less obvious clinical presentation with a pos-
sible delay or lack of diagnosis. Furthermore, a hypothesis of a
south-north axis concerning different expressions of TB has
been put forward since there are less cases of extrapulmonary
TB among the patients born in the Nordic countries compared
with those born in Africa [30]. A similar epidemiological pat-
tern might be valid for Archangelsk since it is located in the
vicinity of the polar circle.
Prisoners are particularly prone to develop TB [31] owing to
the special risk factors within the prison systems, including
poverty, smoking and drug abuse, more prisoners than avail-
able beds, shared bed clothes and restricted time outdoors
[32,33], as well as their primordial health conditions. The pris-
on system has unique possibilities to screen risk groups using
chest X-rays for TB and MDR-TB at admission and regularly,
e.g., every 6 months during imprisonment. An implementa-
tion of rapid molecular biology detection methods for analy-
ses of TB and resistant TB would serve a particular
important cause in this setting. In the Archangelsk region
there are several penal institutions that may interfere with
the civil society from a transmission standpoint, which may
partly explain the high percentage of contagious cases and
resistant pulmonary TB in the civil society.
A rapid method for analysing drug susceptibility of M.
tuberculosis strains is highly cost-effective [2,13]. Appropriate
treatment and isolation procedures for MDR-TB can be rap-
idly implemented and limit transmission to fellow patients
and others. In addition, the cure rate for MDR-TB cases in-
creases, the number of deaths is reduced and the hospitaliza-
tion periods get shorter. The present study confirms the value
of a rapid drug susceptibility method in a high burden setting
such as the Archangelsk region. It is of interest to note the
ample presence of the katG and rpoB mutations making the
GenoType MTBDRplus test particularly well-suited in routine
TB laboratory practice in Archangelsk. Presently, only muta-
tions included in the MDRplus test were analyzed. Further
studies of the complex spectra of mutations resulting in resis-
tance would be of great value.
The M. tuberculosis strains from prisoners were not ana-
lysed by the MTBDRplus method. It can thus not be excludedthat the pattern of molecular genetics responsible for resis-
tance among prisoners differs from the one revealed in the ci-
vil sector. The ample contact between individuals from the
two sectors of the society makes, however, similar patterns
likely.
As is described in Table 4, the sensitivity and specificity of
the assay for the detection of rifampicin, isoniazid resis-
tance and MDR-TB respectively were 96% or above and cor-
respond to results in other settings [9,10]. The sensitivity
rate was similar, though the specificity rate was higher com-
pared with those reported from another Russian study [11].
The results of the MTBDRplus assay, thus, give a firm basis
for therapy decisions in the study setting with its particular
prevalence of M. tuberculosis genotypes and demographic
profile.
Two strains that were mono-resistant to rifampicin were
detected in this study, and similar findings are described by
other authors as well [12,34]. The emergence of resistance is
a dynamic procedure, and rifampicin mono-resistance is an
expected biological phenomenon. Mono-resistance to rifam-
picin is, however, relatively uncommon in many settings,
and is why it has been suggested to test only for rifampicin,
particularly in low-income settings. Since isoniazid is a
key drug in TB treatment, such suggestions need great
cautiousness.
Comparison of the present results from MTBDRplus and
Bactec MGIT 960 revealed that five TB-cases differed. Corre-
sponding findings have been reported in another Russian set-
ting [11] in which discrepant results were found in 12 cases.
Such results may be due to errors that might occur during
the performance of the methods. Other explanations might
be the coexistence of two or more strains (including non
tuberculous mycobacteria) in the same sample and which
poses important clinical questions, such as which therapy re-
gime should be used.
In the prospect of further development of rapid molecular
biology detection methods for the detection of TB, MDR-TB
and extensively drug resistant TB, the conventional methods
may in the future be used for divergent and unclear cases.
The disadvantages of molecular biological techniques
such as the MTBDRplus assay are mainly the need of a well-
equipped laboratory and a skilled laboratory staff. A more ro-
bust method for use in field-like conditions is thus a priority
development goal. The methods are costly, but a wider use
of rapid drug susceptibly testing is nevertheless considered
to be the most cost-effective by WHO [35].
In conclusion, the present study from Archangelsk, Russia,
shows an alarming TB situation with a high number of conta-
gious MDR-TB cases. The Archangelsk Regional Clinical Anti-
tuberculosis Dispensary was among the first laboratories in
Russia that implemented in routine clinical practice the
Genotype MTBDRplus assay, which was shown to be of major
value in this high burden setting.Acknowledgements
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